WHAT: National Institutes of Health (NIH) researchers have developed an animal model of human hantavirus pulmonary syndrome (HPS) in rhesus macaques, an advance that may lead to treatments, vaccines and improved methods of diagnosing the disease. The study, conducted by researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is published in the Proceedings of the National Academy of Sciences.
A sin nombre virus particle emerges from a cell.
Credit: National Institute of Allergy and Infectious Diseases
People become infected with hantaviruses by inhaling virus from the urine, droppings or saliva of infected rodents. This infection can progress to HPS, a severe respiratory disease that was first identified in 1993 in the southwestern United States.
HPS attained global attention in the summer of 2012 when physicians diagnosed 10 cases—three of them fatal—in Yosemite National Park in California. The primary HPS agents are Sin Nombre virus in North America and Andes virus in South America. Since 1993, the Centers for Disease Control and Prevention has reported approximately 600 HPS cases, including 200 deaths, in the United States; case numbers for South America are not available.
In their study, NIAID scientists infected healthy deer mice with Sin Nombre virus obtained from descendants of wild deer mice. The researchers then exposed 10 rhesus macaques to the virus derived from the newly infected deer mice. Nine monkeys became infected and seven developed severe disease.
In the diseased macaques, researchers observed how and where the virus established infection, evaded the immune system and caused pneumonia. Of note, they report that, similar to hantavirus infection in people, the virus in the monkey model triggers a life-threatening immune response nearly two weeks after infection.
NIAID researchers aim to identify biological markers during that initial timeframe that may be useful for early diagnosis.
ARTICLE: Safronetz et al. Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques. Proceedings of the National Academy of Sciences DOI: 10.1073/pnas.1401998111 (2014).
WHO: NIAID Director Anthony S. Fauci, M.D., is available for interviews. David Safronetz, Ph.D., of NIAID’s Laboratory of Virology, also is available.
CONTACT: To schedule interviews, please contact Ken Pekoc, (301) 402-1663, email@example.com.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH...Turning Discovery Into Health®
Ken Pekoc | Eurek Alert!
Snapshots of chemical reactions: Characterizing an important reactive intermediate
01.10.2014 | Academy of Finland
Disease decoded: Gene mutation may lead to development of new cancer drugs
01.10.2014 | University of Michigan
25.09.2014 | Event News
23.09.2014 | Event News
22.09.2014 | Event News
01.10.2014 | Medical Engineering
01.10.2014 | Power and Electrical Engineering
01.10.2014 | Science Education